Publications by authors named "H U Esslinger"
Introduction: Stereotactic body radiation therapy (SBRT) is a treatment for patients with early-stage non-small cell lung cancer (ES-NSCLC). Surveillance guidelines vary after treatment. While patients are more likely to locally recur within 2 years of treatment, there remains a paucity of data on the benefit of frequent and long-term surveillance.
View Article and Find Full Text PDFObjective(s): To assess the influence of treatment package time (TPT) on overall survival (OS) and event free survival (EFS) in oral cavity cancer (OCC) patients treated with surgery and adjuvant radiation therapy (RT) with or without concurrent chemotherapy (CHT).
Materials/methods: 354 adult OCC patients treated at a single, high-volume center between 2012-2022 with various pathologic risk features were included. TPT was defined as days from surgery to RT completion.
Article Synopsis
- Generalizable studies on population-level cancer treatment often overlook variations in individual tumors, making it challenging to predict how a patient will respond to neoadjuvant therapy (NAT) for breast cancer.
- This research evaluates an existing biophysical simulation platform, TumorScope Predict (TS), using data from early-stage and locally advanced breast cancer patients to forecast their response to NAT.
- Among the study cohort of 80 patients, the platform demonstrated a significant correlation between predicted tumor volumes and actual MRI-assessed volumes after treatment, highlighting its potential utility in clinical practice.
Background: The 5-year overall survival of pancreas adenocarcinoma (PCa) remains less than 10%. Clinical and tumor genomic characteristics have not differentiated PCa long-term survivors (LTSs) from unselected patients. Preclinical studies using fecal transplant experiments from LTSs of PCa have revealed delayed tumor growth through unknown mechanisms involving the fecal microbiota.
View Article and Find Full Text PDFObjectives: The goal of this study was to compare outcomes of patients with borderline and resectable pancreatic cancer treated with neoadjuvant stereotactic body radiation therapy (SBRT) versus fractionated chemoradiation.
Methods: Patients with borderline or resectable pancreatic cancer treated with neoadjuvant intent between November 2011 and December 2017 were reviewed. The SBRT volume/dose was 33 Gy in 5 fractions to gross tumor plus abutting vessel with or without 25 Gy in 5 fractions to pancreatic head/body and celiac/superior mesenteric artery.